 Quizartinib at 60-mg/day (vs 30-mg/day) was associated with higher overall response, survival, and bridge to transplant.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease with multiple factors influencing long-term outcome. 1, 2 FLT3 mutations (predominantly internal tandem duplication [ITD] ; reported in ~25% of patients with AML) 3, 4, 5 are common molecular abnormalities in AML. FLT3-ITD mutations are a key oncogenic driver 6, 7, 8, 9 and patients with FLT3 mutated AML have poorer outcomes, lower response rates to chemotherapy, increased risk for relapse, and shorter survival, compared with patients without FLT3 mutation. 4, 10, 11, 12, 13 Consequently, the therapeutic potential of kinase inhibitors targeting Quizartinib is an orally administered, highly potent and selective next-generation tyrosine kinase inhibitor that inhibits FLT3 and is active against ITD mutants. 15, 16, 17 Accumulated clinical experience in phase 1 and 2 clinical trials has shown quizartinib to be highly active in R/R FLT3-ITD mutated AML. 18, 19 In a first-in-human phase 1 study, the maximum tolerated dose of quizartinib was 200 mg orally daily in patients with R/R AML with QT interval corrected using Fridericia's formula (QTcF) prolongation as the dose-limiting toxicity. 18 Quizartinib demonstrated encouraging clinical activity and was associated with a manageable safety profile.
Results also suggested the potential for complete and sustained inhibition of FLT3 phosphorylation. 18 In a subsequent phase 2 study (NCT00989261), efficacy and safety of quizartinib monotherapy was evaluated in 2 independent cohorts: patients ≥60 years of age with R/R AML within 1 year after first-line therapy (Cohort 1), and those ≥18 years of age with R/R disease following salvage chemotherapy or allogeneic hematopoietic stem cell transplant (HSCT) (Cohort 2). 19 Initial treatment with 200 mg/day yielded a higher rate of QTcF prolongation than expected therefore lower doses (90 and 35 mg/day) were explored. QTcF prolongation was reversible and successfully managed by treatment interruption and/or dose reductions. QTcF> 500 msec was reported in 15% and 17% of patients treated with 90 and 135 mg/day, respectively. 19 These results demonstrated that single-agent quizartinib was highly active (CRc rate 
Results

Patient characteristics
Between May 2012 and March 2015, 76 patients were enrolled (ITT population) ( Figure 1 ). Baseline characteristics were generally well balanced between the 2 treatment arms ( unfavorable, 8%; unknown 18%). The frequency of NPM1 and CEBPA mutations were also similar across arms ( Table 1 ). The distribution of FLT3-ITD mutated allelic ratio in the 30mg and 60 mg arms, respectively were: ≥10% to ≤25% (21% and 11%), ≥25% to ≤50% (53% and 34%), and >50% (18% and 45%). There were 3 patients in each arm with FLT3 allele burden <10% at central review confirmation; 2 of whom had undetectable levels (Table 1 ). Patient's received a median 3 prior chemotherapy regimens for AML (range, 1 to 9), 28% of patients had prior HSCT, 92% prior anthracycline, and 15% prior FLT3 inhibitors. Overall, 70% of patients were refractory to their last AML therapy and 30% had documented response (CR or PR) with median duration of response being 6.5 months (range, 0.4 to 18.0 months).
Seventy-four patients received at least 1 dose of quizartinib (30 mg arm, n = 38; 60 mg arm, n = 36) ( Table 2) . Overall, 18 (47%) in the 30 mg arm and 23 (64%) patients in the 60 mg arm had dose reductions/interruptions for management of AEs. As allowed per protocol, 23 of 38 (61%) patients in the 30 mg arm were escalated to 60 mg/day quizartinib and 5 of 36 (14%) patients in the 60 mg arm were escalated to 90 mg/day quizartinib (Table 2 ).
Overall, 24% of patients received concomitant medications with a potential for QTcF prolongation (9 patients in each arm) and 53% received a strong CYP3A inhibitor (18 and 21 patients in the 30 mg and 60 mg arm, respectively) (Appendix 1:
Supplemental Table 1 ).
Efficacy results
Of the 76 patients in the ITT analysis set, 47.4% achieved a best response of CRc (18 patients in each arm (Table 3) . Of the patients achieving CRc, 12 of 18 in the 30 mg arm and 11 of 18 in the 60 mg arm had CRc at the end of Cycle 1. In addition, 5 of 38 patients in the 30 mg arm and 9 of 38 patients in the 60 mg arm achieved PR. Thus, the overall response rate (ORR; defined as CRc+PR) was 61% in 30 mg arm and 71% in the 60 mg arm ( Figure 2 ). Six patients had OS duration ≥ 1 year; 1 in the 30-mg arm and 5 in the 60-mg arm.
Twelve (32%) patients in the 30-mg arm and 16 (42%) in the 60-mg arm bridged to HSCT (Table 3 ). The last recorded response before discontinuing quizartinib for HSCT was CR in 3 patients, CRi in 12 patients, PR in 6 patients, and no response (NR) in 6 patients. One patient did not have a response evaluation prior to HSCT. Patients who bridged to HSCT were not permitted to restart quizartinib following transplant. Four of the 6 long term survivors were patients who bridged to HSCT; 1 in the 30-mg arm and 3 in the 60-mg arm.
Exploratory ad hoc analyses
In an exploratory ad hoc analysis, the CRc rate without dose escalation was 37% 
Safety and toxicity results
Assessment of QTcF prolongation showed that 11% of patients in the 30-mg arm and 17% of patients in the 60-mg arm had QTcF >480 msec (grade 2 or greater) ( Table 4) . Supplemental Table 2 ) were most frequently hematologic; gastrointestinal TEAEs were typically grade ≤2. Adverse events were considered treatment-related in 59 of 74 (80%) patients in the Safety Population. Treatment-related TEAEs (TR-TEAEs; includes both "probably" and "possibly" related AEs) were reported at similar rates across both arms ( Serious adverse events (SAEs) were considered by the investigator treatmentrelated in 10 (26%) patients in the 30-mg arm and 8 (22%) patients in the 60-mg arm.
The most common treatment-related SAEs in the 30-mg arm were febrile neutropenia (3 events) and thrombocytopenia, pericardial effusion, and gastrointestinal hemorrhage (2 events each). The most common treatment-related SAEs in the 60-mg arm included febrile neutropenia and QT prolongation (2 events each). Among deaths not attributed to AML, the leading causes regardless of relationship to treatment were infections and respiratory/thoracic disorders. Two events occurred in the same patient in the 30-mg arm who was dose escalated to 60 mg (fatal pericardial effusion and pleural effusion) that were considered possibly related to study drug.
The majority of patients with elevated liver enzymes had values within 3 to 5 times the upper limit of normal (ULN); no patient met Hy's criteria (bilirubin >2 × ULN concurrently with alanine aminotransferase and/or aspartate aminotransferase >3 × ULN with no increase in alkaline phosphatase) (Appendix 3: Supplemental Table 3 ).
Discussion
Relapsed/refractory FLT3-ITD-positive AML has a poor prognosis and a low response rate to salvage therapy. 
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As HSCT is an important goal for patients with R/R AML, the ability to provide HSCT to more patients is of benefit to patients with an otherwise low probability of longterm survival. In our study, the bridge to HSCT rate in the 60-mg arm (42%) was higher than in the 30-mg arm (32%) and was substantially higher than historical data (8% in the UK NCRI database). 24 This analysis demonstrated that those who were transplanted had a longer OS and quizartinib may offer the opportunity of bridging patients to transplant. 24 Quizartinib was not restarted following transplant in this study; however, it may provide benefit in the post-transplant setting. Based on this, ongoing studies have been designed to allow for the re-initiation of quizartinib therapy after transplant. 25, 26 Consistent with prior Phase 1 and 2 studies, 18, 19 responses were documented in two patients with undetectable FLT3-ITD mutation. The mechanism by which quizartinib induced remission in patients with undetectable FLT3-ITD mutations is unknown and requires further investigation.
Quizartinib was specifically developed to target FLT3 and demonstrates a high specificity for this kinase in vitro. The response rates observed with quizartinib in the current study are comparable to those with gilteritinib in a study with a similar patient population and similar response criteria. 30 Taken together, these findings demonstrate clinically meaningful antitumor activity with quizartinib monotherapy in patients with R/R FLT3-ITD mutated AML.
Quizartinib was generally well tolerated with similar TR-TEAE profiles in both dose groups, possibly because a substantial proportion of patients in the 30 mg arm were dose escalated to 60 mg during the study. The grade 2 or greater incidence of QTcF prolongation of 11% in the 30 mg arm and 17% in the 60 mg arm are of relevance given the higher rates in previous reports with higher doses. 18, 19 Moreover, the incidence of grade 3 QTcF prolongation (>500 msec) was also substantially lower in this study (5% and 3% in 30-mg and 60-mg arms, respectively, with no grade ≥4 events) than in the earlier phase 2 trial using higher quizartinib doses (15% and 17% in 135-mg and 90-mg arms, respectively, with 1 grade 4 event). 19 None of the patients in this study experienced arrhythmias associated with QTcF prolongation while on quizartinib treatment, supporting an acceptable benefit-risk profile for quizartinib in this difficult-totreat patient population. Additional analysis of data from this study regarding pharmacokinetics/pharmacodynamics modeling aimed at examining the relationship between quizartinib dose and QTcF prolongation will be reported in a separate publication.
The phase 2 trial design and sample size may limit the generalizability of the results from this study. In addition, the study was not powered to allow for statistical comparative analyses between arms. The numeric difference in efficacy outcomes between the 30 mg/day and 60 mg/day dose groups may have been influenced by escalation decisions, the rate of dose escalation for lack/loss of response and / or the censoring in CRc duration calculations at the end of treatment for patients bridged to HSCT.
In summary, the totality of evidence from the two Phase 2 studies of quizartinib 
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Sample size 7 How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.
Randomization -- CYP3A, cytochrome P450-isozyme3A.
*30-mg starting dose with permitted escalation to 60 mg for lack of or loss of initial response. †60-mg starting dose with permitted escalation to 90 mg for lack of or loss of initial response. ‡Two patients were randomized but did not receive drug owing to ineligibility. §Clarithromycin is a strong CYP3A inhibitor. QTc, corrected QT interval; and QTcF, QT interval corrected for heart rate by Fridericia's formula.
*30-mg starting dose with permitted escalation to 60 mg for lack of or loss of initial response. †60-mg starting dose with permitted escalation to 90 mg for lack of or loss of initial response. ‡Criteria for maximum QTcF duration and maximum QTcF change from baseline are not mutually exclusive -ie, the same patient could have met either or both criteria. 
